Quest Diagnostics Maintains Neutral Rating with Slight Price Target Adjustment

Quest Diagnostics (DGX) has retained its Neutral rating from UBS analyst Kevin Caliendo, with a slightly lower price target of $175.00 USD. The stock's average target price is $184.61, implying a 10.69% upside from the current price of $166.78. The average brokerage recommendation is 2.2, indicating an "Outperform" status. The estimated GF Value for DGX in one year is $164.26, suggesting a 1.51% downside from the current price.

Quest Diagnostics (DGX) has seen its stock maintain a Neutral rating from UBS analyst Kevin Caliendo, with a slight adjustment in the price target. The new price target is set at $175.00 USD, down from the previous $176.00 USD. This minor adjustment reflects a cautious approach by UBS as they assess the company's market position and future prospects.

The stock's average target price, as reported by analysts, stands at $184.61, suggesting a 10.69% upside from the current price of $166.78. The average brokerage recommendation is 2.2, indicating an "Outperform" status. Additionally, the estimated GF Value for DGX in one year is $164.26, implying a 1.51% downside from the current price.

In the past three months, 7 analysts have published ratings on Quest Diagnostics, offering a range of perspectives from bullish to bearish. The most recent ratings show a shift in sentiment, with no analysts rating the stock as bearish in the last 30 days. The average price target has increased by 4.36% from the previous average of $179.86, indicating a positive outlook among analysts.

Quest Diagnostics reported strong revenue growth of approximately 12% in the first quarter, with nearly 2.5% in organic growth. The company has reaffirmed its revenue and adjusted EPS guidance for the full year 2025, demonstrating confidence in its financial outlook. The company has also expanded its use of automation, robotics, and AI to improve quality, customer, and employee experiences, and productivity.

However, Quest Diagnostics faces challenges, including a potential impact from tariffs and ongoing labor strikes at LifeLabs in British Columbia, which could affect operations and financial performance. Additionally, the company continues to navigate challenges in the health system pricing landscape.

In summary, while Quest Diagnostics faces some headwinds, the stock maintains a positive outlook with a Neutral rating and a slightly lower price target. The average target price and brokerage recommendation suggest potential upside, but investors should closely monitor the company's performance and the evolving market conditions.

References:
[1] https://www.marketbeat.com/stocks/NYSE/DGX/
[2] https://www.gurufocus.com/news/2987499/quest-diagnostics-dgx-faces-slight-price-target-adjustment-by-ubs-dgx-stock-news
[3] https://www.benzinga.com/insights/analyst-ratings/25/07/46502505/where-quest-diagnostics-stands-with-analysts